PPT-Multi Drug Resistant Tuberculosis (MDR-TB) Among HIV-Positive Patients in A Tertiary

Akujobi CN Okoro CE Anyabolu AE Okonkwo RC Onwunzo MC and Chukwuka CP Tuberculosis TB is the most common opportunistic infection in Human Immuno d eficiency Virus HIV. We would like to remind you that this material is the property of the author.. It is provided to you by the ERS for your personal use only, as submitted by the author. . 2012 by the author. Evolution of TB control and elimination strategies. Bruce A. Bush, M.D.. Regional Tuberculosis Consultant. Pennsylvania Department of Health. Senior Vice President for Medical Affairs. Indiana Regional Medical Center. Disclosures. I do not have any financial arrangements or affiliations with a commercial entity.. Mycobacterial . Disease. . Increasing . Role for Surgery, Relearning Old Lessons. John D. Mitchell, M.D.. Professor and Chief. Section of General Thoracic Surgery. Davis Endowed Chair in Thoracic Surgery. update 2011. Between 2011 and 2015 …. Increase in TB cases tested for R & H yearly from 0.8 million to 1.9 million. 1 . million . multidrug-resistant TB (. MDR-TB) . patients detected and put on treatment. Naira Dekhil. 1. , . Besma. Mhenni. 1. , Raja Haltiti. 2. , and . Helmi. Mardassi. 1. . (speaker).  . 1. Unit of Typing & Genetics of . Mycobacteria. , . Institut. Pasteur de Tunis, . Tunisia. Prof JG . Hakim, . Parirenyatwa. . CRS . Leader. Annual Research . Day; 8. th. . April 2016. TB- A Global Problem. TB Transformative Science Group (TB TSG). Agenda. Treatment & prevention of TB with or without HIV co-infection. ries 14 61 contributed data on 17690 isolates whichThese drugs are more costly toxic and less effective thanfirst-line drugs used for routine treatment of TB with other diseases resistance to TB drugs Dr.. . Mohit. Bhatia. Assistant Professor. Department of Microbiology. AIIMS, . Rishikesh. LAYOUT. Introduction to Mycobacteria. Laboratory Diagnosis. General Features of Mycobacteria. Acid fastness . [NAME OF PRESENTER]. [TITLE OF PRESENTER]. STREAM Clinical Trial. Overview of the presentation. Outline. Burden of disease. TB treatments. Conclusions. Status of MDR TB in the world. Status of MDR/RR-TB . with multi-resistant virus. 6 APRIL 2020. Faculty. Pedro . Cahn. , Buenos-Aires, Argentina. Anton . Pozniak. , London, UK. François . Raffi. , Nantes, France. Faculty Disclosures. Pedro Cahn. has received research support for research grants: . — 91 — and extensively drug resistant TB — 92 — and extensively drug resistant TBficient anti TB programs were the most affected by multi-resistance. Global resistance figures prov Álvarez-Narváez S, Giguère S, Cohen N, Slovis N, Vázquez-Boland JA. Spread of Multidrug-Resistant Rhodococcus equi, United States. Emerg Infect Dis. 2021;27(2):529-537. https://doi.org/10.3201/eid2702.203030. * Tuberculosis, Drug Resistance, and the History of Modern Medicine. Salmaan Keshavjee and Paul Farmer. N Engl J Med. 2012 Sep 6;367(10):931-6.. ". Tuberculosis, whether caused by drug-susceptible or drug-resistant strains, rarely made even medical headlines, in part because its importance as a cause of death continued to decline in areas in which headlines are written.”. KENYA. Back ground. Tuberculosis is a disease of public health . importance: . i. ts mode of transmission.. The upsurge of drug resistance especially MDR and XDR . WHO TB report 2016. Estimated MDR/RR-TB cases among 1 300 notified pulmonary TB cases..